CD Protein Inhibitors Immunotherapy Immune Checkpoint Inhibitors Tyrosine Kinase Inhibitors BCL Inhibitors Other RAR/RXR Wnt Signaling Inhibitors | Chronic Lymphocytic Leukemia | Non Small Cell Lung Cancer | Diffuse Large B Cell Lymphoma | T Acute Lymphoblastic Leukemia | Adenoid Cystic Carcinoma | Prolymphocytic Leukemia | Mantle Cell Lymphoma | Triple Negative Breast Cancer | Squamous Cell Carcinoma of Head and Neck | Colorectal Cancer |
---|---|---|---|---|---|---|---|---|---|---|
zanubrutinib | ||||||||||
venetoclax + ibrutinib | ||||||||||
tislelizumab | ||||||||||
tretinoin | ||||||||||
rituximab | ||||||||||
obinutuzumab + GS-9973 | ||||||||||
venetoclax | ||||||||||
Compound E | ||||||||||
nirogacestat | ||||||||||
WNT974 | ||||||||||
CB-839 | ||||||||||
IACS-010759 | ||||||||||
ofatumumab | ||||||||||
BMF-219 | ||||||||||
obinutuzumab | ||||||||||
ibrutinib + rituximab + obinutuzumab | ||||||||||
Immunotherapy | ||||||||||
ibrutinib | ||||||||||
sintilimab + fruquintinib |